Cervical adenosquamous carcinoma
diseaseOn this page
Also known as adenosquamous cell carcinoma of cervixadenosquamous cell carcinoma of cervix uteriadenosquamous cell carcinoma of the cervixadenosquamous cell carcinoma of the cervix uteriadenosquamous cell carcinoma of the uterine cervixadenosquamous cell carcinoma of uterine cervixcervical adenosquamous cancercervical adenosquamous cell carcinomacervix adenosquamous cell carcinomacervix uteri adenosquamous cell carcinomauterine cervix adenosquamous cell carcinoma
Summary
Cervical adenosquamous carcinoma (MONDO:0006134) is a cancer and 47 clinical trials. Top therapeutic interventions include cisplatin, methylene blue cation, and topotecan hydrochloride. A subtype of cervical adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 47
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | cervical adenosquamous carcinoma |
| Mondo ID | MONDO:0006134 |
| EFO | EFO:1000162 |
| DOID | DOID:5636 |
| NCIT | C4519 |
| SNOMED CT | 254888007 |
| UMLS | C0346202 |
| MedGen | 91091 |
| GARD | 0024303 |
| Is cancer (heuristic) | yes |
Also known as: adenosquamous cell carcinoma of cervix · adenosquamous cell carcinoma of cervix uteri · adenosquamous cell carcinoma of the cervix · adenosquamous cell carcinoma of the cervix uteri · adenosquamous cell carcinoma of the uterine cervix · adenosquamous cell carcinoma of uterine cervix · cervical adenosquamous cancer · cervical adenosquamous carcinoma · cervical adenosquamous cell carcinoma · cervix adenosquamous cell carcinoma · cervix uteri adenosquamous cell carcinoma · uterine cervix adenosquamous cell carcinoma
Data availability: 6 cell lines.
Disease family
This is a subtype of cervical adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › cervical adenocarcinoma › cervical adenosquamous carcinoma
Related subtypes (9): endocervical adenocarcinoma, uterine ligament adenocarcinoma, cervical mucinous adenocarcinoma, Wolffian duct adenocarcinoma, cervical serous adenocarcinoma, cervical endometrioid adenocarcinoma, early invasive cervical adenocarcinoma, cervical adenoid cystic carcinoma, cervical clear cell adenocarcinoma
Subtypes (1): cervical adenosquamous carcinoma, glassy cell variant
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 47.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 18 |
| PHASE1 | 10 |
| PHASE3 | 8 |
| Not specified | 8 |
| PHASE1/PHASE2 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02466971 | PHASE3 | ACTIVE_NOT_RECRUITING | Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers |
| NCT07061977 | PHASE3 | RECRUITING | Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer |
| NCT00017004 | PHASE3 | COMPLETED | Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia |
| NCT00064077 | PHASE3 | COMPLETED | Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix |
| NCT00262821 | PHASE3 | TERMINATED | Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer |
| NCT00803062 | PHASE3 | COMPLETED | Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer |
| NCT01101451 | PHASE3 | COMPLETED | Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent Surgery |
| NCT01414608 | PHASE3 | COMPLETED | Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer |
| NCT02257528 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer |
| NCT06543576 | PHASE1/PHASE2 | RECRUITING | External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer |
| NCT06805864 | PHASE2 | NOT_YET_RECRUITING | Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma |
| NCT07153952 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | RT for Adenocarcinoma/Adenosquamous Carcinoma |
| NCT07276360 | PHASE2 | RECRUITING | Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda |
| NCT00039442 | PHASE2 | COMPLETED | Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer |
| NCT00057863 | PHASE2 | COMPLETED | Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer |
| NCT00217633 | PHASE2 | COMPLETED | Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer |
| NCT00309959 | PHASE2 | COMPLETED | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer |
| NCT00369122 | PHASE2 | COMPLETED | Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer |
| NCT00389974 | PHASE2 | COMPLETED | Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery |
| NCT00416455 | PHASE1/PHASE2 | COMPLETED | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer |
| NCT00924066 | PHASE2 | TERMINATED | Ixabepilone to Treat Cervical Cancer |
| NCT01026792 | PHASE2 | COMPLETED | Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery |
| NCT01266447 | PHASE2 | COMPLETED | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer |
| NCT01266460 | PHASE2 | COMPLETED | Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer |
| NCT01267253 | PHASE2 | COMPLETED | Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer |
| NCT02868892 | PHASE2 | TERMINATED | A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas |
| NCT02921269 | PHASE2 | COMPLETED | Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer |
| NCT03469531 | PHASE2 | UNKNOWN | Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer |
| NCT03834571 | PHASE2 | WITHDRAWN | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women |
| NCT02595879 | PHASE1 | ACTIVE_NOT_RECRUITING | Triapine With Chemotherapy and Radiation Therapy in Treating Patients With IB2-IVA Cervical or Vaginal Cancer |
| NCT07454642 | PHASE1 | RECRUITING | AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors |
| NCT00068549 | PHASE1 | COMPLETED | Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer |
| NCT00104910 | PHASE1 | COMPLETED | Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer |
| NCT01281852 | PHASE1 | COMPLETED | Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer |
| NCT01295502 | PHASE1 | UNKNOWN | Cisplatin and Radiation Therapy Followed by Paclitaxel and Carboplatin in Treating Patients With Stage IB-IVA Cervical Cancer |
| NCT01711515 | PHASE1 | COMPLETED | Chemoradiation Therapy and Ipilimumab in Treating Patients With Stages IB2-IIB or IIIB-IVA Cervical Cancer |
| NCT02020707 | PHASE1 | COMPLETED | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers |
| NCT02164461 | PHASE1 | COMPLETED | Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer |
| NCT03738228 | PHASE1 | COMPLETED | Atezolizumab Before and/or With Chemoradiotherapy in Immune System Activation in Patients With Node Positive Stage IB2, II, IIIB, or IVA Cervical Cancer |
| NCT01649089 | Not specified | ACTIVE_NOT_RECRUITING | Studying the Physical Function and Quality of Life Before and After Surgery in Patients With Stage I Cervical Cancer |